Another year of "315", are the pharmaceutical machine companies still on pins and needles?

[Pharmaceuticals.
com Market Analysis] It's the annual Consumer Rights Day again.
Every year, "315" attracts the attention of consumers.
Which industries will the fraudulent behaviors be exposed at this year's "315 Party"? Which companies will be on the "Black List Oscar"? Many netizens have been waiting for this annual drama to be staged
.

For some enterprises, it can be described as "sit on pins and needles", with the sword of Damocles hanging above the head
.

 Another year of "315", are the pharmaceutical machine companies still on pins and needles? Which consumption problems will be more serious in 2021? Recently, the China Consumers Association released the "Analysis Report on Complaints Accepted by the National Consumers Association in 2021"
.

The report shows that in 2021, the National Consumers Association will accept a total of 1.
0448 million consumer complaints, a year-on-year increase of 6.
37%
.

Judging from the nature of complaints, after-sales service, contract issues and quality issues still account for a relatively high proportion, accounting for 31.
54%, 27.
22% and 20.
00% respectively
.

Compared with 2020, in 2021, the proportion of after-sales service, contract problems and counterfeiting problems that consumers complain about will decrease, but prices, false publicity, and quality problems will increase
.

 　　According to the data, it can be seen that in 2021, the company will improve its after-sales service level, but it still needs to be paid attention to in terms of integrity promotion and quality issues
.

 　　The proportion of complaints about medicines and medical supplies has decreased.
According to the complaint data of major categories of commodities in 2021, household electrical appliances, daily commodities, food, clothing, shoes and hats, and transportation have the highest number of complaints.
Medicines and medical supplies also have the highest number of complaints.
Ranked at the top, with a total of 9,849 complaints
.

However, compared with the 35,000 complaints in 2020, the proportion of complaints about medicines and medical supplies dropped by 2.
64%
.

It can be seen that the pharmaceutical and medical supplies industry has made some efforts to protect the rights and interests of consumers
.

 　　Pharmaceutical products are special commodities and are closely related to human health and safety
.

In recent years, with the improvement of people's living standards, the enhancement of health and wellness awareness, and the intensification of population aging, the market demand for medicine and medical care has continued to expand
.

 　　In order to promote the high-quality development of the pharmaceutical industry, relevant departments in China have issued a number of policies in recent years, intensified special rectification efforts, strengthened the supervision of all aspects of medicine, improved the quality of medicines, and protected the rights and interests of consumers
.

 　　In fact, not only the pharmaceutical industry, but also the upstream pharmaceutical equipment industry has received more attention from the industry because it is related to the quality of medicines
.

 　　In the past, due to its late start and low technical level, China's pharmaceutical equipment industry was mainly based on low-level repeated production.
The phenomenon of counterfeiting and shoddy products in the market was common.
Therefore, it was concluded that domestic pharmaceutical machines are inferior to imported ones
.

In addition, due to the weak awareness of intellectual property rights of domestic enterprises and the difficulty of industry supervision, some unscrupulous manufacturers who have opened Internet sales channels sell fake products at low prices under the names of other companies, which not only damages the rights and interests of consumers, but also damages regular enterprises.
The reputation of the whole market brings "pollution" to the environment of healthy development and fair competition of the whole market
.

 　　In recent years, with the rapid development of the pharmaceutical industry, especially biological drugs, the pharmaceutical equipment industry has ushered in new opportunities for development.
At the same time, since 2020, with the delayed delivery of imported equipment, domestic pharmaceutical machines have gradually entered the stage.
The pace of import substitution has accelerated
.

 　　In the long run, the import substitution space for domestic pharmaceutical machines is very broad, especially in the mid-to-high-end field, there is still a large market to be tapped
.

However, compared with imported equipment, domestic pharmaceutical machine companies still need to continue to increase investment in research and development, improve the level of innovation, quality, and after-sales service, etc.
, to meet the actual needs of modern pharmaceutical companies, in order to be comparable to high-end imported products
.

 　　At present, domestic leading pharmaceutical machine companies represented by Chutian Technology and Tofflon are strengthening their research and development efforts, continuously expanding their talent teams, and creating higher-end domestic equipment.
user needs
.

Promote the entire industry to upgrade from the low-end to the mid-to-high end
.

 　　Conclusion "315 Gala" is not only to expose the behavior of a certain brand to defraud consumers, but more to protect the rights and interests of consumers in the process of consumption, and also bring warning to related industries
.

For the pharmaceutical machine industry, under the background of the industry ushering in a new round of development opportunities, it is necessary to adhere to the original intention, operate with integrity, focus on the actual needs of users, and continuously improve the company's own hard core strength in terms of product quality and after-sales service.
, in order to be no longer on pins and needles when 315 comes
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.